IL‐1 and IL‐1 regulatory pathways in cancer progression and therapy

• Published in: Immunological reviews Vol. 281; no. 1; pp. 57 - 61
• Main Authors: Mantovani, Alberto, Barajon, Isabella, Garlanda, Cecilia
• Format: Journal Article
• Language: English
• Published: England Wiley Subscription Services, Inc 01.01.2018
• Subjects: Angiogenesis; Animals; Cancer; Carcinogenesis; Carcinogens; Humans; Immunomodulation; Immunotherapy - methods; Inflammation; inflammation‐associated cancer; Interleukin 1; Interleukin 1 receptor antagonist; Interleukin 1 receptors; Interleukin 17; Interleukin-1 - metabolism; Interleukin-17 - metabolism; Macrophages; Metastases; Myeloid-Derived Suppressor Cells - physiology; Neoplasm Metastasis; Neoplasms - immunology; Neovascularization, Pathologic; Receptors, Interleukin-1 - metabolism; Regulators; Signal Transduction; Suppressor cells; therapy; Tumor Microenvironment; Tumors; interleukin-1; inflammation; inflammation-associated cancer; therapy
• ISSN: 0105-2896; 1600-065X; 1600-065X
• DOI: 10.1111/imr.12614

Summary Inflammation is an important component of the tumor microenvironment. IL‐1 is an inflammatory cytokine which plays a key role in carcinogenesis and tumor progression. IL‐1 is subject to regulation by components of the IL‐1 and IL‐1 receptor (ILR) families. Negative regulators include a decoy receptor (IL‐1R2), receptor antagonists (IL‐1Ra), IL‐1R8, and anti‐inflammatory IL‐37. IL‐1 acts at different levels in tumor initiation and progression, including driving chronic non‐resolving inflammation, tumor angiogenesis, activation of the IL‐17 pathway, induction of myeloid‐derived suppressor cells (MDSC) and macrophage recruitment, invasion and metastasis. Based on initial clinical results, the translation potential of IL‐1 targeting deserves extensive analysis.